Today: November 20, 2018, 6:20 am
  
Business

Groupe Ecore Holding S.A.S. Proposed Senior Secured Floating Rate Notes Offering

PR-Inside.com: 2018-11-08 13:52:01

Groupe Ecore Holding S.A.S. Proposed Senior Secured Floating Rate Notes Offering

Groupe Ecore Holding S.A.S.
Thomas Boublil
Chief Financial Officer
Thomas.Boublil@ecore.com

Groupe Ecore Holding S.A.S. (the “Issuer”) announces that it intends to offer €255 million in aggregate principal amount of senior secured floating rate notes due 2023 (the “Notes”). Interest will be paid quarterly based on three-month EURIBOR (with 0% floor). The Notes will be senior obligations of the Issuer and will be guaranteed on a senior basis by Ecore B.V.

Application will be made to The International Stock Exchange Authority Limited for the listing of and permission to deal in the Notes on the Official List of The International Stock Exchange.

Disclaimer

This announcement does not constitute an offer to sell or the solicitation of an offer to buy the Notes or any other security and shall not constitute an offer, solicitation or sale in the United States or in any jurisdiction in which, or to any persons to whom, such offering, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any jurisdiction.

The Notes and the related guarantees have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") and may not be offered or sold within the United States or to, or for the account or benefit of, U.S. persons except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

This announcement may include projections and other "forward-looking" statements within the meaning of applicable securities laws. Any such projections or statements reflect the current views of the Company about future events and financial performance. The use of any of the words "expect," "anticipate," "continue," "will," "project," "should," "believe," "plans," "intends" and similar expressions are intended to identify forward-looking information or statements. Although the Company believes that the expectations and assumptions on which such forward-looking statements and information are reasonable, undue reliance should not be placed on the forward-looking statements and information because the Company can give no assurance that such statements and information will prove to be correct. Since forward-looking statements and information address future events and conditions, by their very nature they involve inherent risks and uncertainties.

The forward-looking statements and information contained in this announcement are made as of the date hereof and the Company undertakes no obligation to update publicly or revise any forward-looking statements or information, whether as a result of new information future events or otherwise, unless so required by applicable securities laws. Within the United Kingdom, this announcement is directed only at persons having professional experience in matters relating to investments who fall within the definition of "investment professionals" in Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 ("relevant persons"). The investment or investment activity to which this announcement relates is only available to and will only be engaged in with relevant persons and persons who receive this announcement who are not relevant persons should not rely or act upon it.

Manufacturer target market (MIFID II product governance) is eligible counterparties and professional clients only (all distribution channels). No PRIIPs key information document (KID) has been prepared as not available to retail in EEA.

Press Information


Published by
Hossam Abdel-Kader
+43 1 9582319
e-mail
http://www.pr-inside.com/


# 584 Words
Related Articles
More From The Author
ADC Therapeutics Announces Presentations at the Society [..]
Potential new immune-oncology therapy uses antibody drug conjugate (ADC) that targets regulatory T cells (Tregs) Highly potent [..]
TBC Bank wins the Best Private Bank [..]
TBC Bank has been named the Best Private Bank in Georgia 2018 by Professional Wealth Management (PWM) and The Banker [..]
Merus to Present at the Jefferies 2018 [..]
UTRECHT, The Netherlands, Nov. 08, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing [..]
Vectura Group announces global agreement with Hikma [..]
Vectura Group announces global agreement with Hikma to develop generic versions of GSK’s Ellipta® portfolio  Upfront payment [..]
Brookfield Asset Management Reports Third Quarter 2018 [..]
Net Income of $941 million or $0.11 per share,FFO of $1.1 billion or $1.07 per share BROOKFIELD, Nov. 08, 2018 (GLOBE [..]
 
More From Business
Best Essential Oil Diffusers on the Market
19 November 2018 – Got Oil Supplies offers a wide variety of aromatherapy diffusers that you can choose from, depending [..]
UK Business Energy – Best Spot to [..]
London, United Kingdom – 19BNovember 2018 – UK Business Energy offers an excellent opportunity to compare all energy tariffs [..]
The Greatest Biosoft Gels From Cancer by [..]
17th November 2018 - Purtier Placenta provides interesting products for everyone. If you are ready to start your experience with [..]
Get Flavors for Your Electronic Cigarette from [..]
17th November 2018 - Vapeshack provides great services for those who are ready to pay for comfort. Are you a [..]
The Very Efficient Instagram Boosting Services from [..]
17th November 2018 - Social Result is a very user friendly and informative platform, for those who are ready to [..]

Disclaimer: If you have any questions regarding information in this press release please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims the content included in this release.